MZMinghao Zhong

Minghao Zhong

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Minghao Zhong has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Youfeng Yang

    Urologic Oncology Branch

    3 shared publications
  • Lisa Osborne

    Institute of Genomic Medicine, University of Medicine and Dentistry of New Jersey—New Jersey Medical School, Newark, NJ

    2 shared publications
  • Maria J. Merino

    Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, Bethesda, MD

    2 shared publications
  • Patricia De Angelo

    Institute of Genomic Medicine, University of Medicine and Dentistry of New Jersey—New Jersey Medical School, Newark, NJ

    2 shared publications
  • W. Marston Linehan

    Urologic Oncology Branch

    2 shared publications
  • Alberto E. Paniz-Mondolfi

    St Luke’s-Roosevelt Hospital Center, New York

    1 shared publication

Latest Publications

  • Xp11.2 Translocation Renal Cell Carcinoma With PSF-TFE3 Rearrangement

    by Minghao Zhong, Paul Weisman, Bing Zhu, Maria Brassesco, Youfeng Yang, W. Marston Linehan, Maria J. Merino, David Zhang, Stephen Rohan, Dongming Cai, et al.

    Xp11.2 translocation renal cell carcinoma (Xp11.2 RCC) is a subtype of RCC characterized by translocations involving a breakpoint at the TFE3 gene (Xp11.2). Moderate to strong nuclear TFE3 immunoreactivity has been recognized as a specific diagnostic marker for this type of tumor. However, exclusive cytoplasmic localization of a TFE3 fusion protein was reported in UOK 145 cells, a cell line derived from an Xp11.2 RCC harboring the PSF-TFE3 translocation. If reproducible using immunohistochemistry (IHC), this finding would have important implications for pathologists in the diagnosis of Xp11.2 RCC, calling into question the specificity of nuclear immunoreactivity for TFE3 in these tumors. The purpose of this study was to determine whether the above-noted cytoplasmic localization of the TFE3 fusion protein could be reproduced using IHC. UOK 145 cells and fresh frozen tissue from 2 clinical cases of Xp11.2 RCC found to harbor the PSF-TFE3 gene rearrangement (by cytogenetic testing) were collected. All samples were subjected to histopathologic evaluation by board-certified pathologists, TFE3 IHC, reverse transcription polymerase chain reaction, and Sanger sequencing analysis. A strong nuclear TFE3 immunoreactivity was demonstrated in all samples including the UOK 145 cell line. No cytoplasmic immunoreactivity was seen. Reverse transcription polymerase chain reaction and Sanger sequencing confirmed the previously reported PSF-TFE3 gene fusion between exon 9 of PSF and exon 6 of TFE3 in the UOK 145 cell line and in one of 2 clinical cases of Xp11.2 RCC. A novel PSF-TFE3 gene fusion between exon 9 of PSF and exon 5 of TFE3 was detected in the second clinical case of Xp11.2 RCC.


  • Translocation Renal Cell Carcinomas in Adults

    by Minghao Zhong, Patricia De Angelo, Lisa Osborne, Alberto E. Paniz-Mondolfi, Matthew Do Geller, Youfeng Yang, W. Marston Linehan, Maria J. Merino, Carlos Cordon-Cardo, Dongming MD Cai

    Translocation renal cell carcinoma is a newly recognized subtype of renal cell carcinoma (RCC) with chromosomal translocations involving TFE3 (Xp11.2) or, less frequently, TFEB (6p21). Xp11 translocation RCC was originally described as a pediatric neoplasm representing 20% to 40% of pediatric RCCs, with a much lower frequency in the adult population. TFEB translocation RCC is very rare, with approximately 10 cases reported in the literature. Here, we describe the clinicopathologic features of adult translocation RCC from a single institution. Using tissue microarray, immunohistochemistry, cytogenetic examination, and fluorescence in situ hybridization, we identified 6 (∼5%) cases of TFE3 translocation RCC and 1 (TFEB translocation RCC in 121 consecutive adult RCC cases between 2001 and 2009. Our results suggest that weak TFE3 staining of a significant proportion of RCC cases may be because of expression of the full-length TFE3 protein rather than the chimeric fusion protein resulting from chromosomal translocation.


  • Dual-color, Break-apart FISH Assay on Paraffin-embedded Tissues as an Adjunct to Diagnosis of Xp11 Translocation Renal Cell Carcinoma and Alveolar Soft Part Sarcoma

    by Minghao Zhong, Patricia De Angelo, Lisa Osborne, Megan Keane-Tarchichi, Michael Goldfischer, Lisa Edelmann, Youfeng Yang, W. Marston Linehan, Maria J. Merino, Seena Aisner, et al.

    Both Xp11.2 translocation renal cell carcinoma (RCC) and alveolar soft part sarcoma (ASPS) are characterized by various translocations disrupting chromosome Xp11.2, which result in gene fusions involving the TFE3 transcription factor gene. Diagnostic tools to detect translocations involving the TFE3 gene on chromosome X would be valuable in the evaluation of these tumors. We developed a dual-color, break-apart fluorescence in situ hybridization (FISH) assay to identify the chromosomal break point in paraffin-embedded tissue. This assay was validated using 4 cases of Xp11.2 RCC [proven by karyotype and/or reverse-transcriptase polymerase chain reaction (RT-PCR)], 2 cases of ASPS (proven by karyotype or RT-PCR), the UOK109 cell line carrying the inv(X) (p11;q12), and several negative controls (both neoplastic and non-neoplastic). This break-apart FISH assay is a relatively quick procedure for detecting Xp11.2 RCC and ASPS translocations and can be applied to archival paraffin-embedded tissue.